STOCK TITAN

Halozyme to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Halozyme Therapeutics, Inc. (HALO) senior leadership team to present at Piper Sandler 35th Annual Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference. CFO Nicole LaBrosse and President/CEO Helen Torley to host investor meetings in New York and Miami, respectively, on November 29th, 2023. Live audio webcast and replays available on the company's website.
Positive
  • None.
Negative
  • None.

SAN DIEGO, Nov. 27, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences. 

Details on the presentations are as follow:

Event:




Piper Sandler 35th Annual Healthcare Conference

Presenter:




Nicole LaBrosse, Chief Financial Officer

Format:




Fireside Chat and 1x1 Meetings

Presentation Date:




Wednesday, November 29th, 2023

Presentation Time:




5:00 a.m. PT / 8:00 a.m. ET

Location:




New York, NY






Event:




6th Annual Evercore ISI HealthCONx Conference

Presenter:




Helen Torley, President and Chief Executive Office

Format:




Fireside Chat and 1x1 Meetings

Presentation Date:




Wednesday, November 29th, 2023

Presentation Time:




9:30 a.m. PT / 12:30 p.m. ET

Location:




Miami, FL






A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED® and TLANDO® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Dawn Schottlandt 
Argot Partners
212-600-1902
Halozyme@argotpartners.com

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-301997522.html

SOURCE Halozyme Therapeutics, Inc.

Halozyme will be presenting on Wednesday, November 29th, 2023.

Helen Torley, President and Chief Executive Officer, will be presenting.

The live audio webcast will be available in the Investor Relations section of the company's website, with replays available for 90 days following the conference.
Halozyme Therapeutics Inc.

NASDAQ:HALO

HALO Rankings

HALO Latest News

HALO Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
San Diego

About HALO

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies